Article
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2018
Romaniello Donatella, Mazzeo Luigi, Mancini Maicol, Marrocco Ilaria, Noronha Ashish, Kreitman Matthew, Srivastava Swati, Ghosh Soma, Lindzen Moshit, Salame Tomer Meir, Onn Amir, Bar Jair, Yarden Yosef
Abstract excerpt
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due to new mutations or bypass mechanisms. We examined in animals and in vitro an alternative therapeutic approach making use of antibodies.Experimental Design: An osimertinib-sensitive animal model of lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.